Allogene to present pre-clinical data for next-gen AlloCAR T candidate

Allogene Therapeutics announced that it will present pre-clinical data for its next-generation investigational AlloCAR T candidate for autoimmune indications, ALLO-329, at the American College of Rheumatology’s annual meeting, ACR Convergence 2024, being held from November 14-19 in Washington, D.C. ALLO-329, the Company’s CD19/CD70 dual AlloCAR T product is the first CAR T designed to both reduce or eliminate the need for lymphodepletion while also targeting CD19+ B-cells and CD70+ activated T-cells, both of which are likely to play a role in autoimmune diseases. ALLO-329 utilizes CRISPR-based site-specific integration for dual CAR expression.